Executive Summary : | The global incidence of cancer, particularly oral cancer, is increasing, and traditional treatments include surgery, chemotherapy, and radiotherapy. However, immune response-based therapy is gaining importance. NLRP3, an inflammatory marker, directly correlates with cancer progression. Few studies have explored the molecular mechanisms behind the cross-talk between NLRP3 inflammasome and oral cancers. This study aims to understand these mechanisms and determine their potential therapeutic role in oral cancers. It will also evaluate the role of phytochemical 6-Shogaol in inducing anti-oral cancer immunity through the NLRP3 pathway. The study will also study innate immune profiles and mucosal or gut immunity cells in oral cancer tumors, adjacent normal tissue, saliva, and peripheral blood to identify prognostic markers. The study will evaluate 6-shogaol derived from natural self-renewable resources and known NLRP3 inhibitors for their anti-cancer efficacy and mucosal immunity. |